CHU de Tours

Running trials

• Recruiting

  French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic Disorders, Autism Spectrum Disorders, and Healthy Controls

  NCT07881016· Source

• Recruiting

  Study of Alloknesia in Atopic Dermatitis

  NCT06923202· Source

• Recruiting

  Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease

  NCT07257289· Source

• Not yet recruiting

  Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors

  NCT06798532· Source

• Recruiting

  Epidemiological Data on Mast Cell Pathologies in France

  NCT06186856· Source

• Recruiting

  French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis

  NCT06147843· Source

• Recruiting

  Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

  NCT05945524· Source

• Active, not recruiting

  Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

  NCT06062537· Source

• Recruiting

  A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

  NCT05639413· Source

• Recruiting

  Contact Aspiration Versus Stent Retriever for Recanalisation of Acute Stroke Patients With Basilar Artery Occlusion: The Posterior Circulation ASTER Randomized Trial Protocol

  NCT05320263· Source

• Recruiting

  TARGETed Therapy Drug MONITOring in DIGestive Oncology

  NCT05443087· Source

• Recruiting

  AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

  NCT05198960· Phase 3· Source

• Active, not recruiting

  PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

  NCT04664465· Source

• Recruiting

  A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

  NCT03755726· Source

• Active, not recruiting

  Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis

  NCT03981003· Source

• Active, not recruiting

  IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

  NCT03744390· Phase 2· Source

• Active, not recruiting

  OFSEP High Definition Cohort

  NCT03603457· Source

• Recruiting

  French National Database of Rare Dermatological Cancers

  NCT03210935· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• ALS (motor neurone disease)1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study

  NCT05314140· Source

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· Source

• Completed

  Effect of Vibratory Tendon Stimulation on Muscle Fatigue in the Acute Post-stroke Phase

  NCT06296225· Source

• Completed

  Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT

  NCT05524324· Source

• Completed

  Partial Nephrectomy in Low Pressure

  NCT05404685· Source

• Completed

  Interrupters of VAscular daMAge in Malignant Hypertension

  NCT04991077· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits

  NCT04111211· Source

• Terminated

  "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer"

  NCT03876561· Source

• Completed

  Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis

  NCT03293069· Phase 2/3· Source

• Completed

  Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

  NCT03458260· Phase 2· Source

• Terminated

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· Source

• Terminated

  Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

  NCT03117972· Phase 2· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Source

• Completed

  Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

  NCT02649790· Phase 1/2· Source